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In patients with cancer, particularly those receiving cytotoxic
chemotherapy, anaemia is a common occurrence (Groopman and
Itri, 1999). The condition can have a profound effect on many
aspects of quality of life (QOL), such as exercise capacity, fatigue
and mood (Cella, 1997). However, studies indicate that anaemia
and its most frequent manifestation, fatigue, are under-recognized
and under-treated (Vogelzang et al, 1997; Lawless et al, 2000).
Several factors may contribute to seemingly suboptimal manage-
ment of anaemia in cancer patients. These reasons relate to lack of
awareness among physicians, inadequacies of current treatments,
and the existence of several key outstanding issues regarding the
general management of cancer-related anaemia. This review first
summarizes the evidence showing the significance and benefits of
treating anaemia in cancer patients and discusses the key factors
contributing to the apparent under-treatment of anaemia. 
INCIDENCE OF CANCER-RELATED ANAEMIA 
Anaemia may develop as a result of the malignant disease process
itself; from bleeding, nutritional deficiencies, bone marrow
damage, tumour infiltration of the bone marrow, or immunologic
impairment of erythropoietic response. However, it probably
occurs most often by iatrogenic means, as a consequence 
of myelosuppressive chemotherapy or radiotherapy (Beguin,
1996). 
Several researchers have measured the incidence of anaemia in
cancer patients (Coiffier, 1998; Dalton et al, 1998; Groopman 
and Itri, 1999). In a broad review of published clinical trials,
Groopman and Itri (1999) found that the incidence of Grade 1 to 2
and Grade 3 to 4 anaemia after chemotherapy can be as high as
100% and 80%, respectively. The incidence of anaemia varies
depending on tumour type and chemotherapy regimen. For
example, the combination of cisplatin and etoposide, one of the
most widely used regimens for advanced small-cell lung cancer,
produced Grade 3 or 4 anaemia in 16 to 55% of patients. However,
the combination of 5-fluorouracil and leucovorin in advanced
colorectal cancer produced Grade 3 or 4 anaemia in only 2 to 5%
of patients. 
Chemotherapy undoubtedly contributes to the development of
anaemia, and this incidence increases over the course of therapy
(Coiffier, 1998; Dalton et al, 1998). Coiffier (1998) studied 1064
patients with a variety of malignancies receiving chemotherapy, in
whom the mean baseline haemoglobin was > 12 g dl–1 in all but
two tumour groups. By the third cycle of chemotherapy, nearly
two-thirds of patients were anaemic, of whom 28% were
mildly anaemic (haemoglobin 10.5 to 12 g dl–1), 34% were
moderately anaemic (haemoglobin 8 to 10.5 g dl–1), and 5% were
severely anaemic (haemoglobin < 8 g dl–1). In a separate study of
2821 patients receiving cytotoxic chemotherapy, an average of
17% of patients were anaemic (haemoglobin < 11 g dl–1) before the
first cycle (Dalton et al, 1998). This figure increased to 35% by the
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doi: 10.1054/ bjoc.2001.1750, available online at http://www.idealibrary.com on sixth cycle. On average, 33% of patients required at least one red
blood cell transfusion because of anaemia. 
Anaemia after radiotherapy also appears to be common. In a
study by Harrison et al (2000), 48% of patients presenting for
radiotherapy for solid tumours were anaemic (haemoglobin
< 12 g dl–1) before treatment; this figure increased to 57% with the
completion of therapy. 
IMPACT OF ANAEMIA ON QUALITY OF LIFE 
Anaemia can affect many aspects of QOL and can result in func-
tional deficits such as decreased exercise capacity, headaches,
dyspnoea, loss of libido, and dizziness (Cella, 1997). This lowers
the subjective sense of well-being and impairs other important
aspects of patients’ lives such as the ability to work, interact
socially, and enjoy leisure activities (Yellen et al, 1997). 
One of the most pronounced, and most studied, clinical symp-
toms of anaemia is fatigue (Khayat, 2000). Fatigue is the most
prevalent symptom reported by patients with cancer, and has report-
edly been regarded by patients as more important than nausea and
vomiting (Stone et al, 2000). In a recent survey, approximately
three-quarters of patients with cancer receiving chemotherapy (with
or without radiotherapy) reported experiencing fatigue (defined as a
‘general feeling of debilitating tiredness or loss of energy’) (Curt
et al, 2000). Fatigue has a large impact on QOL (Cella, 1997), and
91% of patients reported that it prevented them from leading a
‘normal’ life (Curt et al, 2000). For 61% of patients, fatigue was
more significant than cancer-related pain (Vogelzang et al, 1997).
Fatigue also affects work schedules, with employed patients using
an average of 4.2 sick/vacation days per month, during or immedi-
ately after treatment, as a direct result of fatigue (Curt et al, 2000). 
Despite the impact on patients’ QOL, oncologists are commonly
reluctant to treat fatigue (Vogelzang et al, 1997; Curt, 2000).
Seventy-seven percent of patients who discussed fatigue with their
oncologists reported that they were told that fatigue was some-
thing they had to endure, and 40% were told that there was nothing
their oncologist could do (Vogelzang et al, 1997). Only 6% of
oncologists prescribed medication for fatigue, according to
patients (Curt et al, 2000). However, when oncologists were ques-
tioned in a separate survey regarding the importance of treating
fatigue, 80% believed that fatigue is overlooked or under-treated
by their peers (Vogelzang et al, 1997). 
In patients with cancer, anaemia and fatigue are closely linked,
but this association is not easy to characterize. Just as fatigue is not
the only symptom of anaemia, anaemia is not the only cause of
fatigue. Although fatigue may be multifactorial, anaemia is an
important contributing factor to fatigue in cancer patients and one
that can be treated. 
An objective correlation exists between haemoglobin values
and QOL in patients with cancer (Cella, 1997; Yellen et al, 1997).
Cella (1997) developed and tested derivations of the Functional
Assessment of Cancer Therapy (FACT) measurement systems that
were specifically designed to evaluate the impact of fatigue
(FACT-F) or anaemia (FACT-An) on QOL in cancer patients. The
results clearly showed that patients with haemoglobin values
>1 2g  d l –1 experienced significantly less fatigue, fewer non-
fatigue anaemia symptoms, better physical well-being, better func-
tional well-being, and higher general QOL than those whose
haemoglobin was < 12 g dl–1. Furthermore, haemoglobin values
were shown to be associated with overall QOL, with patients with
higher haemoglobin values experiencing a higher QOL. 
BENEFITS OF TREATING ANAEMIA 
Improved quality of life 
Numerous studies, both placebo-controlled and open-label, have
consistently shown that increasing haemoglobin values has a
measurable and significant effect on QOL parameters in cancer
patients whether they are receiving (Abels, 1993; Case et al, 1993;
Henry and Abels, 1994; Leitgeb et al, 1994; Glaspy et al, 1997;
Demetri et al, 1998) or not receiving concurrent chemotherapy
(Ludwig et al, 1995). In all of these studies, haemoglobin was
increased by the administration of recombinant human erythro-
poietin (rHuEPO, epoetin alfa). 
Large-scale clinical trials designed to study the effect of
rHuEPO on QOL in the setting of community oncology practice
rather than in the more artificial environment of a phase 3 clinical
trial have provided compelling and consistent data showing the
importance of treating anaemia in cancer patients (Glaspy et al,
1997; Demetri et al, 1998). In an open-label study, in which
rHuEPO was administered to 2342 patients receiving cytotoxic
chemotherapy, patients’ mean energy levels increased by 38%,
activity increased by 32%, and overall QOL increased by 24%
after 4 months of therapy, all significant increases (P < 0.001)
(Glaspy et al, 1997). A later study involving 2370 patients
reported similar results, noting that increased haemoglobin values
from baseline were associated with improved activity level,
energy, and overall well-being (Figure 1). Furthermore, a direct
and statistically significant association was shown by regression
analysis between the increase in overall QOL and the increase in
haemoglobin level from baseline (r = 0.235; P < 0.001) (Demetri
et al, 1998). 
The beneficial effect of rHuEPO was shown to be independent
of anti-tumour response in a prospective analysis of 2117 patients
(Demetri et al, 1998). Patients who had no increase in haemo-
globin values did not experience a significant increase in QOL,
regardless of whether they achieved a complete or partial response
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Figure 1 Change from baseline to final quality of life (QOL) score by
haemoglobin change. Activity, energy, and overall QOL were assessed using
linear analogue scales and analysed based on corresponding haemoglobin
value changes. *Significantly different from baseline (P < 0.01). 
† Significantly different from adjacent haemoglobin change group (P < 0.01).
Reproduced with kind permission of Lippincott Williams & Wilkins from
Demetri et al (1998) to chemotherapy, or had stable disease. Direct and statistically
significant correlations between haemoglobin value change and
change in overall QOL for complete response after chemotherapy
(r = 0.242; P < 0.001), partial response (r = 0.275; P < 0.001), and
stable disease (r = 0.253; P < 0.001) were shown, but not for
progressive disease (r = 0.084; P = 0.072). Patients with progres-
sive disease experienced some benefits from an increase in haemo-
globin; however, the magnitude of the effect in this subset of
patients, as one might expect, was far less than in patients whose
tumours were controlled by anticancer therapy. 
Cleeland et al (1999) analysed the results from the open-label
trials by Glaspy et al (1997) and Demetri et al (1998) and showed
that the largest improvement in QOL occurred when haemoglobin
values increased from 11 to 12 g dl–1. This relationship was main-
tained after controlling for tumour type and status, transfusions,
number of days on study, the extent of chemotherapy and radio-
therapy, and feelings of pain and/or nausea. This result clearly
shows the benefits of even small increases in haemoglobin and
demonstrates that a decrease in haemoglobin to only slightly
below normal levels is frequently associated with significant
reductions in QOL. 
Possibilities for improved treatment outcomes 
Many studies have found that inadequate oxygenation at the
tumour site and/or low haemoglobin values are associated with
poor treatment outcome after curative radiotherapy (Fein et al,
1995; Dubray et al, 1996; Fyles et al, 1998; Grogan et al, 1999).
Adequate tumour oxygenation is known to be necessary for an
optimal response to radiotherapy (Glaspy and Cavill, 1999), thus it
is theoretically possible that decreased haemoglobin (which may
contribute to lowered oxygenation at the tumour site) may also
have an effect on the success of therapy. 
In a study of 74 patients with cervical cancer, disease-free
survival was statistically significantly associated with tumour
oxygenation (P = 0.02) (Fyles et al, 1998). Other studies have
shown a statistically significant association between anaemia and
reduced local control or survival in cervical cancer or head and
neck cancer (Fein et al, 1995; Dubray et al, 1996; Warde et al,
1998; Grogan et al, 1999). Dubray et al (1996) found that even
moderate anaemia significantly correlated with a worse treatment
outcome in squamous cell carcinoma of the head and neck (Figure 2).
However, it is unclear whether low haemoglobin directly
contributes to reduced tumour control and survival after radio-
therapy, or whether it is merely a marker of advanced disease in
patients for whom successful treatment outcomes are less likely,
regardless of tumour oxygenation. Thus, randomized, controlled
trials are needed to assess the effect of anaemia correction on
survival and disease control. 
ISSUES IN THE CURRENT MANAGEMENT OF
ANAEMIA 
Anaemia is widely believed to be under-recognized and under-
treated (Glaspy et al, 1997; Ludwig, 1999). Most physicians do not
administer transfusions until severe anaemia develops (haemo-
globin < 8 to 9 g dl–1) (Coiffier, 1998; Estrin et al, 1999; Glaspy
and Harper, 2000; Throuvalas et al, 2000) and a recent survey of
3472 patients treated by 20 community oncologists found that 52
to 70% of anaemic patients (haematocrit < 30%) undergoing
chemotherapy did not receive treatment with rHuEPO (Lawless et
al, 2000). 
There are several possible explanations why anaemia is under-
treated: lack of awareness of the incidence and impact of anaemia;
inadequacies in the current treatment options; and the existence of
several key uncertainties surrounding the management of anaemic
cancer patients. 
Lack of awareness of the incidence and impact of
anaemia 
Despite the overwhelming evidence supporting the value of treating
anaemia, and particularly that described as ‘functional’ anaemia, it
appears that many physicians are reluctant to administer therapy.
Treatment is usually reserved for patients with severe anaemia,
when haemoglobin values decrease to 8 or 9 g dl–1 or serious
cardiovascular symptoms are apparent (Glaspy and Harper, 2000).
This failure to administer therapy until haemoglobin has decreased
to such a low level may be attributed, at least in part, to lack of
awareness of the benefits of treating anaemia, particularly mild-to-
moderate anaemia. A lack of awareness of the high incidence of
anaemia accompanying particular malignancies and chemotherapy
regimens is also likely to contribute to the low rate of treatment. 
Inadequacies in the current treatment options 
Transfusions 
Red blood cell transfusions are a rapid and reliable method of
correcting anaemia, particularly in cases where anaemia is life-
threatening. However, many real and perceived risks are associ-
ated with the procedure, such as infection, allergic and/or febrile
reactions, and the theoretical risk of transfusion-associated
immunosuppression (Ludwig and Fritz, 1998a; Goodnough et al,
1999) (Table 1). In addition, there is the inconvenience, to both
clinician and patient, of administering the transfusions for only
transient benefit. For patients who may already be myelo-
suppressed and feeling poorly, the risks of allergic and febrile reac-
tions to transfusions are not favourable. Furthermore, patients
often express very strong preferences to avoid undergoing trans-
fusion (Table 2). 
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Figure 2 Actuarial probability of overall survival according to anaemic
status. The haemoglobin cut-off level for anaemia was 13.5 g dl–1 for men
and 12 g dl–1 for women. Reproduced with kind permission of the
Radiological Society of North America Inc. from Dubray et al (1996) Recombinant human erythropoietin 
Despite the well-documented efficacy of rHuEPO in increasing
haemoglobin and reducing the need for transfusions, this agent is
still not used routinely for the management of patients receiving
chemotherapy as it is for the support of haemoglobin levels in
patients with other chronic diseases such as renal failure. This
under-use may be due in part to the limitations of this therapy,
including less-than-optimal response rates and the lack of
adequate reliable predictors of response (Table 2). In addition,
several outstanding issues remain to be clarified, such as the
optimal dose and schedule, and when to stop or increase the dose
of the drug. 
Inconvenience of rHuEPO Inconvenience may seem a minor
limitation of rHuEPO therapy to some healthcare providers,
however, to patients it may be of great importance. Since the
original regulatory approval of rHuEPO, it has been recommended
that rHuEPO be given 3 times weekly, a schedule that does not
always correspond with the administration of chemotherapy. The
use of once-weekly dosing, recently reported by Gabrilove et al
(1999), may help alleviate this problem and encourage greater
patient compliance. 
Suboptimal response rates to rHuEPO For the 50 to 60% of
patients who respond to therapy (variably defined as an increase in
haemoglobin ³ 2g  d l –1 or an increase in haematocrit of ³ 6%),
rHuEPO is an effective and well-tolerated treatment, increasing
haemoglobin values, reducing the need for transfusions, and
improving overall QOL (Abels, 1993; Leitgeb et al, 1994; Glaspy
et al, 1997; Demetri et al, 1998). However, therapy is ineffective
for the 40 to 50% of patients who do not respond, and the
relatively slow time to response may cause some patients and
physicians to terminate rHuEPO therapy prematurely due to lack
of perceived benefit. In one series of patients, the median time to
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Table 1 Risks of complications from blood transfusions 
Risk factor Estimated frequency No. deaths per million units
Per million units Per actual unit 
Infection 
Viral 
Hepatitis A 1 1/1 000 000 0
Hepatitis B 7–32 1/30 000–1/250 000 0–0.14
Hepatitis C 4–36 1/30 000–1/150 000 0.5–17
HIV 0.4–5 1/200 000–1/2 000 000 0.5–5
HTLV types I and II 0.5–4 1/250 000–1/2 000 000 0 
Parvovirus B19 100 1/10 000 0
Bacterial contamination 
Red cells 2 1/500 000 0.1–0.25 
Platelets 83 1/12 000 21
Acute haemolytic reactions 1–4 1/250 000–1/1 000 000 0.67
Delayed haemolytic reactions 1000 1/1000 0.4
Transfusion-related acute 200 1/5000 0.2 
lung injury
HIV = human immunodeficiency virus; HTLV = human T-cell lymphotropic virus. 
Reproduced with kind permission of the Massachusetts Medical Society from Goodnough et al, 1999. Copyright © 1999 Massachusetts Medical Society. All
rights reserved. 
Table 2 Limitations of current therapies for anaemia 
Transfusions rHuEPO 
Inconvenient Effective in only 50–60% of patients 
Transient benefit Response can take 4 weeks or longer to occur 
Patients’ preference to avoid No adequate predictors of response 
Risk of infections Administration not necessarily synchronized with chemotherapy 
Tumour potentiation due to immune suppression (as yet unproven) Frequent injections require numerous patient visits 
Haemolytic reactions Tumour potentiation (as yet unproven) 
Risk of allergic reactions
Iron overload
Volume expansion 
Loss of efficacy in patients with antibodies 
Only minor impact on quality of life
Supply is limited 
Handling is time-consuming
Adapted from Ludwig and Fritz (1998a) and ProcritTM prescribing information (Ortho Biotech, 1999). response was approximately 4 weeks, but it may require as long as
12 weeks to determine responsiveness in an individual patient
(Ludwig and Fritz, 1998b). Clearly, administering and monitoring
response to therapy for up to 3 months for no ultimate gain is not
ideal. Almost half of those patients (44%) who fail to respond to
the initial dose of rHuEPO will respond to an increased dose
(Demetri et al, 1998); however, predicting these responders has not
been possible by any prospective indicators. 
Predicting response to rHuEPO Potentially, the impact of the
less-than-optimal response rates can be lowered if physicians are
able to predict, before commencement of therapy, which patients
are likely to respond and thus direct treatment at these patients. An
alternative method is to identify non-responsive patients early in the
treatment course and terminate ineffective therapy appropriately. 
Many potential predictive factors have been studied, including
pre-treatment erythropoietin (EPO) levels (Abels, 1992; Cascinu
et al, 1994) and changes in indicators of erythropoietic response
measured 2 to 4 weeks after commencement of treatment (Ludwig
et al, 1994; Glaspy et al, 1997). However, although numerous vari-
ables (haemoglobin, EPO, ferritin, neopterin, C-reactive protein,
transferrin receptors, transferrin, serum iron, haematocrit, red
blood cells, reticulocytes and a1-antitrypsin), measured after 2
weeks, have been found to significantly correlate with response,
none was associated strongly enough to serve as a reliable single
prognostic indicator (Ludwig et al, 1994). Of the factors studied,
the change in haemoglobin value after 2 weeks proved the most
reliable. 
Based on these analyses, Ludwig et al (1994) predicted that, if
after 2 weeks of therapy the serum EPO level is ³ 100 mU ml–1
and haemoglobin value has not increased by at least 0.5 g dl–1, the
patient is unlikely to respond to rHuEPO (predictive power, 93%);
otherwise response may be predicted with an accuracy of 80%
(Ludwig et al, 1994). Conversely, if the serum EPO level is < 100
mU ml–1 and haemoglobin value has increased by ³ 0.5 g dl–1, the
patient is very likely to respond (predictive power, 95%). 
With the use of increased doses of rHuEPO, however, it may not
be prudent to immediately classify patients as unresponsive
because they did not achieve an increase in haemoglobin at the
standard dose. In the trial by Demetri et al (1998), patients whose
haemoglobin increased by < 1 g dl–1 received a doubled dose of
rHuEPO (to 20 000 U 3 times weekly). Of these, 44% went on to
achieve either an increase in haemoglobin of ³ 2g  d l –1 or a haemo-
globin level ³ 12 g dl–1 by the end of the study, demonstrating that
initial failure to respond does not necessarily indicate that a patient
will not benefit from increased doses of rHuEPO. 
Thus, despite much research, highly reliable predictors of
response to rHuEPO do not exist, making the targeting of rHuEPO
therapy to appropriate patients difficult. Complications such as
infections and functional iron deficiency, which can impair
response to rHuEPO, may further confound the problem (Beguin,
1998). 
Cost Red blood cell transfusions have historically been viewed
as less expensive than rHuEPO (Ludwig and Fritz, 1998a;
Mercadante et al, 2000). It is difficult, however, to gain a current,
accurate measurement of the cost of acquiring, handling,
processing, storing and administering blood; the costs associated
with the complications of transfusions; and the indirect economic
costs to patients due to travelling to a transfusion centre and/or
absence from work. One analysis placed the cost of collecting,
testing, and administering blood, and treating complications at
£192 (US$324) per transfusion (Dalton et al, 1998). A more recent
retrospective study of 517 patients with haematologic or solid
tumours estimated the cost of a two-unit transfusion to be US$938,
but did not take into consideration the cost of treating
complications (Cremieux et al, 2000). As the combination of fewer
donations and increased demand decreases the supply of available
blood and the number of sophisticated screening tests rises,
transfusion costs are likely to increase. 
Pharmacoeconomic analyses are therefore needed that incorpo-
rate (a) the cost of transfusions (handling and administering blood,
and managing complications); (b) the economic consequences of
lost productivity associated with administering transfusions; (c)
the cost of administering rHuEPO once the optimal dose and
schedule is identified; and (d) the cost of administering rHuEPO
once physicians are able to target therapy to those patients most
likely to respond and/or terminate therapy once a response is ruled
out. Furthermore, the economic costs of lost productivity by
patients who are unable to work due to symptomatic anaemia must
be considered, and the psychological costs of patient preferences
to avoid transfusions should also be taken into account. 
Outstanding issues Further studies using rHuEPO are needed
to address additional issues such as the optimal dose and schedule
(Glaspy et al, 1997), when to stop the drug because of lack of
response, and when to increase the dose (Mercadante et al, 2000).
It has been suggested that an initial dose of rHuEPO of 150 U kg–1
is given three times weekly subcutaneously, which is increased to
300 U kg–1 if the haemoglobin value does not increase by ³ 1g  d l –1
after 4 weeks of therapy. A patient who does not respond to the
doubled dose is unlikely to respond to higher doses (Glaspy et al,
1997) and should therefore have therapy terminated at this point.
However, whether this treatment pattern is followed in routine
clinical practice or results in the most efficient and effective use of
the agent is unclear. 
Key uncertainties surrounding the management of
anaemic cancer patients 
Monitoring, identifying and effectively treating anaemic cancer
patients is not an easy task. Physicians must consider many issues
on a regular basis to ensure that their patients do not develop, and
subsequently suffer, the effects of anaemia. 
An issue that is currently unclear is exactly how to determine an
appropriate trigger point for therapeutic intervention. That is, if a
patient’s haemoglobin value is decreasing, which criteria should
be used to determine the point at which the patient requires
therapy? Clearly, physical symptoms should be considered as well
as haemoglobin value. The study by Cleeland et al (1999) showed
that the greatest improvements in QOL occur when haemoglobin
values increase from 11 to 12 g dl–1. This suggests that a haemo-
globin value at or below 11 g dl–1 may be an appropriate
trigger point in those patients whose symptoms have not already
necessitated intervention. However, as some patients experience
the effects of anaemia before their haemoglobin decreases below
11 g dl–1, it seems unlikely that using a standard haemoglobin
value as a trigger point will identify all patients who could benefit
from therapy with an erythropoietic agent. 
Thus, it is prudent to consider both symptoms and haemoglobin
values before making treatment decisions; however, the relative
value placed on each measurement remains to be defined.
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anaemia becomes debilitating to receive treatment. If anaemic
patients can be identified and treated while their haemoglobin
values are decreasing, and before the symptoms of anaemia
appear, therapy can be initiated before severe anaemia develops. 
As studies show that many, but not all, cancer patients experi-
ence anaemia (Coiffier, 1998; Dalton et al, 1998; Groopman and
Itri, 1999; Harrison et al, 2000), it would be of great benefit to be
able to predict whether a patient is at high risk of developing
anaemia and/or has a low tolerance to the complications of
anaemia and blood transfusions. Such knowledge would assist
physicians in monitoring patients more closely and/or adminis-
tering therapy with an erythropoietic agent before anaemia
becomes symptomatic. A recent study by Ray-Coquard et al
(1999) may assist in this goal; however, it requires validation in a
large, multicentre study. 
Finally, there are no universally accepted guidelines addressing
the most effective methods of monitoring cancer patients for
anaemia, and once identified, managing the condition. The devel-
opment of such guidelines may assist in improving current treat-
ment practices and result in more widespread and effective
management of anaemic patients with cancer. 
THE FUTURE 
A recent addition to the family of growth factors is darbepoetin
alfa (ARANESPTM, Amgen Inc, Thousand Oaks, CA).
Darbepoetin alfa is a novel erythropoiesis stimulating protein
(NESP), and represents a new generation of erythropoiesis stimu-
lating proteins.  A license application has been filed worldwide for
its use to treat renal anaemia, and it is under further development
in the oncology-haematology setting.
Experimental evidence demonstrating a direct relationship
between the amount of sialic acid-containing carbohydrate side
chains on rHuEPO, and serum half-life and in vivo biological
activity prompted the development of NESP. This protein has an
increased sialic acid content and thus, an approximately 3-fold
longer serum half-life than rHuEPO and increased biological
activity (Egrie et al, 1997; Macdougall et al, 1999). NESP binds to
EPO receptors and stimulates erythropoiesis (Macdougall, 2000).
In animal studies, NESP was approximately 3.6 times as potent as
rHuEPO in increasing the haematocrit in normal mice when
injected three-times weekly and was 20-fold more efficacious than
rHuEPO when both agents were given in a once-weekly dosing
schedule (Egrie et al, 1997). 
NESP has undergone clinical testing in more than 2000 oncology
and chronic renal failure patients. The agent was well tolerated
in clinical trials, with no evidence of antibody formation
(Vanrenterghem et al, 1999; Glaspy et al, 2000; Kotasek et al, 2000;
Macdougall, 2000; Tseng et al, 2000; Glaspy et al, 2001;
Heatherington et al, 2001; Smith et al, 2001). Pharmacokinetic
studies in patients with renal failure demonstrated that NESP has a
serum half-life of approximately 50 hours after subcutaneous
administration (Macdougall et al, 1999). Large clinical trials demon-
strated that NESP is effective in the treatment of renal anaemia and
that once-weekly and once every second week dosing with the agent
is possible, using both the intravenous and subcutaneous routes of
administration (Macdougall, 1998; Vanrenterghem et al, 1999). 
Following the success of NESP in treating renal anaemia, trials
are currently underway (the preliminary results from three of
which are included in this supplement) to assess the value of the
agent in treating anaemia of cancer (Glaspy et al, 2001;
Heatherington et al, 2001; Smith et al, 2001). The dose-escalation
study involving 107 patients with solid tumours conducted by
Glaspy et al (2001), in which the agent was administered once-
weekly to patients receiving chemotherapy, demonstrates a
dose–response relationship between NESP and haemoglobin
increase. Preliminary data from the dose-escalation study by
Smith et al (2001) indicate that NESP is also effective in patients
not receiving chemotherapy. At a dose of 2.25 mcg kg–1 wk–1 of
NESP, 72% of patients corrected their haemoglobin values
(haemoglobin  ³ 12 g dl–1). Time to response was shorter in those
patients receiving higher doses of NESP. Heatherington et al
(2001) confirmed an extended half-life of NESP in patients with
cancer, supporting the possibility that this therapy can be adminis-
tered less frequently. In fact, a phase 1–2 trial has demonstrated
that administration of NESP once every 3 weeks may be clinically
effective (Kotasek et al, 2000). 
Thus, the data so far show that NESP, through its longer half-
life, increased biological activity and less frequent dosing, has
great potential to improve the management of anaemia in patients
with cancer. Less frequent dosing will allow administration to be
more easily synchronized with chemotherapy, and may reduce the
compliance burden on the patient and health care resources. 
CONCLUSIONS 
Anaemia and fatigue are common among cancer patients and have
a measurable impact on QOL. However, anaemia, and particularly
mild-to-moderate anaemia, appears under-recognized and under-
treated in the practice of oncology. There are several possible
reasons for this, some of which can be overcome by increased
awareness of the problem posed by anaemia and the clarification
of key management issues. Many of the current limitations of
rHuEPO may be overcome by the introduction of NESP into
routine clinical practice. The data reported so far are encouraging,
and reduced dosing frequency, with the potential for more rapid
responses, should translate to a reduced burden on both patients
and health care resources. Further trials will determine the full
potential of NESP in the management of cancer-related anaemia;
in the meantime, physicians must remain alert to the development
of anaemia in their patients and ensure that patients are managed
as effectively as possible. 
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